The effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients: Prospective randomized study with volumetric intravascular ultrasonography analysis

Sung Hye You, Beum Suk Kim, Soon Jun Hong, Chul Min Ahn, Do-Sun Lim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background and Objectives: Pioglitazone has been known for its anti-atherogenic effects. We compared the effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients. Subjects and Methods: This was a prospective, randomized single-blinded, 8-month follow-up study. Patients with significant coronary artery stenosis were randomly assigned to either pioglitazone (n=19) or placebo (n=18) following zotarolimus-eluting stent (ZES) implantation. Intravascular ultrasonography of the culprit vessel was performed from 20 mm distal and proximal to the stent at baseline. and at 8-month, and volumetric analysis was performed. Changes in inflammation markers, insulin resistance and lipid profile were compared. Results: Changes in atherosclerosis progression from baseline in the pioglitazone group was significantly lower than that of the placebo group (0.06±0.73 vs. 1.16±1.41 mm 3/mm, p=0.024, respectively), and neointima volume was significantly lower in the pioglitazone group compared to the placebo group ( 1.74±0.93 vs. 2.42±1.98 mm 3/mm, p=0.007, respectively). Homeostatic model assessment-index, interleukin-6, and tumor necrosis factor-α levels were significandy lower in the pioglitazone group at 8 months. Adiponectin levels increased significantly only in the pioglitazone group. No significant differences in retinol binding protein-4 levels between the 2 groups were seen during the 8-month follow-up period. Conclusion: Compared to placebo, pioglitazone was associated with significant reduction in atherosclerosis progression and neointima formation in type 2 diabetic patients with ZES implantation.

Original languageEnglish
Pages (from-to)625-631
Number of pages7
JournalKorean Circulation Journal
Volume40
Issue number12
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

pioglitazone
Interventional Ultrasonography
Neointima
Atherosclerosis
Prospective Studies
Placebos
Stents
Retinol-Binding Proteins
Coronary Stenosis
Adiponectin

Keywords

  • Diabetes mellitus
  • Intravascular ultrasonography
  • Neointima
  • Pioglitazone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

@article{f0f6f81b9ad14f1eafb6a51eb42031e4,
title = "The effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients: Prospective randomized study with volumetric intravascular ultrasonography analysis",
abstract = "Background and Objectives: Pioglitazone has been known for its anti-atherogenic effects. We compared the effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients. Subjects and Methods: This was a prospective, randomized single-blinded, 8-month follow-up study. Patients with significant coronary artery stenosis were randomly assigned to either pioglitazone (n=19) or placebo (n=18) following zotarolimus-eluting stent (ZES) implantation. Intravascular ultrasonography of the culprit vessel was performed from 20 mm distal and proximal to the stent at baseline. and at 8-month, and volumetric analysis was performed. Changes in inflammation markers, insulin resistance and lipid profile were compared. Results: Changes in atherosclerosis progression from baseline in the pioglitazone group was significantly lower than that of the placebo group (0.06±0.73 vs. 1.16±1.41 mm 3/mm, p=0.024, respectively), and neointima volume was significantly lower in the pioglitazone group compared to the placebo group ( 1.74±0.93 vs. 2.42±1.98 mm 3/mm, p=0.007, respectively). Homeostatic model assessment-index, interleukin-6, and tumor necrosis factor-α levels were significandy lower in the pioglitazone group at 8 months. Adiponectin levels increased significantly only in the pioglitazone group. No significant differences in retinol binding protein-4 levels between the 2 groups were seen during the 8-month follow-up period. Conclusion: Compared to placebo, pioglitazone was associated with significant reduction in atherosclerosis progression and neointima formation in type 2 diabetic patients with ZES implantation.",
keywords = "Diabetes mellitus, Intravascular ultrasonography, Neointima, Pioglitazone",
author = "You, {Sung Hye} and Kim, {Beum Suk} and Hong, {Soon Jun} and Ahn, {Chul Min} and Do-Sun Lim",
year = "2010",
month = "12",
day = "1",
doi = "10.4070/kcj.2010.40.12.625",
language = "English",
volume = "40",
pages = "625--631",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "12",

}

TY - JOUR

T1 - The effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients

T2 - Prospective randomized study with volumetric intravascular ultrasonography analysis

AU - You, Sung Hye

AU - Kim, Beum Suk

AU - Hong, Soon Jun

AU - Ahn, Chul Min

AU - Lim, Do-Sun

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Background and Objectives: Pioglitazone has been known for its anti-atherogenic effects. We compared the effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients. Subjects and Methods: This was a prospective, randomized single-blinded, 8-month follow-up study. Patients with significant coronary artery stenosis were randomly assigned to either pioglitazone (n=19) or placebo (n=18) following zotarolimus-eluting stent (ZES) implantation. Intravascular ultrasonography of the culprit vessel was performed from 20 mm distal and proximal to the stent at baseline. and at 8-month, and volumetric analysis was performed. Changes in inflammation markers, insulin resistance and lipid profile were compared. Results: Changes in atherosclerosis progression from baseline in the pioglitazone group was significantly lower than that of the placebo group (0.06±0.73 vs. 1.16±1.41 mm 3/mm, p=0.024, respectively), and neointima volume was significantly lower in the pioglitazone group compared to the placebo group ( 1.74±0.93 vs. 2.42±1.98 mm 3/mm, p=0.007, respectively). Homeostatic model assessment-index, interleukin-6, and tumor necrosis factor-α levels were significandy lower in the pioglitazone group at 8 months. Adiponectin levels increased significantly only in the pioglitazone group. No significant differences in retinol binding protein-4 levels between the 2 groups were seen during the 8-month follow-up period. Conclusion: Compared to placebo, pioglitazone was associated with significant reduction in atherosclerosis progression and neointima formation in type 2 diabetic patients with ZES implantation.

AB - Background and Objectives: Pioglitazone has been known for its anti-atherogenic effects. We compared the effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients. Subjects and Methods: This was a prospective, randomized single-blinded, 8-month follow-up study. Patients with significant coronary artery stenosis were randomly assigned to either pioglitazone (n=19) or placebo (n=18) following zotarolimus-eluting stent (ZES) implantation. Intravascular ultrasonography of the culprit vessel was performed from 20 mm distal and proximal to the stent at baseline. and at 8-month, and volumetric analysis was performed. Changes in inflammation markers, insulin resistance and lipid profile were compared. Results: Changes in atherosclerosis progression from baseline in the pioglitazone group was significantly lower than that of the placebo group (0.06±0.73 vs. 1.16±1.41 mm 3/mm, p=0.024, respectively), and neointima volume was significantly lower in the pioglitazone group compared to the placebo group ( 1.74±0.93 vs. 2.42±1.98 mm 3/mm, p=0.007, respectively). Homeostatic model assessment-index, interleukin-6, and tumor necrosis factor-α levels were significandy lower in the pioglitazone group at 8 months. Adiponectin levels increased significantly only in the pioglitazone group. No significant differences in retinol binding protein-4 levels between the 2 groups were seen during the 8-month follow-up period. Conclusion: Compared to placebo, pioglitazone was associated with significant reduction in atherosclerosis progression and neointima formation in type 2 diabetic patients with ZES implantation.

KW - Diabetes mellitus

KW - Intravascular ultrasonography

KW - Neointima

KW - Pioglitazone

UR - http://www.scopus.com/inward/record.url?scp=79551714212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551714212&partnerID=8YFLogxK

U2 - 10.4070/kcj.2010.40.12.625

DO - 10.4070/kcj.2010.40.12.625

M3 - Article

C2 - 21267384

AN - SCOPUS:79551714212

VL - 40

SP - 625

EP - 631

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 12

ER -